LitAlert ~~ GeneLit.com

    • What 20 years of research has taught us about the TP53 p.R337H mutation.
    • Pinto EM, Zambetti GP.
    • Cancer. 2020 Aug 17. doi: 10.1002/cncr.33143. [Epub ahead of print]
    • Parent of Origin Effects on Family Communication of Risk in BRCA+ Women: A Qualitative Investigation of Human Factors in Cascade Screening.
    • Dwyer AA, Hesse-Biber S, Flynn B, Remick S.
    • Cancers (Basel). 2020 Aug 17;12(8):E2316. doi: 10.3390/cancers12082316.
  • ☺☺

    • Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland.
    • Rogoza-Janiszewska E, Malinska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T, Lener M, Górski B, Kluzniak W, Rudnicka H, Akbari MR, Kashyap A, Narod SA, Lubinski J, Debniak T.
    • Cancers (Basel). 2020 Aug 17;12(8):E2321. doi: 10.3390/cancers12082321.
    • Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer.
    • Wan Q, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y.
    • Fam Cancer. 2020 Aug 17. doi: 10.1007/s10689-020-00202-4. [Epub ahead of print]
    • Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk.
    • Ray T.
    • GenomeWeb. 2020 Aug 6.
    • Basket Trial Data Supports Further Study of Lynparza, Imfinzi Regimen in BRCA-Mutated Breast Cancer.
    • Ray T.
    • Precision Oncology News. 2020 Aug 12.
    • Research news